The data shows: CXMT’s over-allotment option was exercised in full, injecting an additional 870 million yuan into its war chest. But the real story is not the money—it’s the signal.
Over the past 7 days, the market has been digesting the full exercise of the greenshoe option for ChangXin Memory Technologies (CXMT) on its Shanghai IPO. The underwriter, CICC, did not buy a single share from the secondary market to stabilize the price. That means demand was strong enough to absorb the entire 8.7 billion yuan offering without artificial support. On the surface, this is a bullish sign. But as a data detective, I don’t trust surfaces. I trace the hash to find the human error.
Context: The Over-Allotment Mechanism and CXMT’s Position
CXMT is China’s only DRAM IDM (Integrated Device Manufacturer), currently ranked 4th globally with a ~3-5% market share. The IPO raised approximately 80 billion yuan, with the over-allotment adding another 8.7 billion yuan. The full exercise of the greenshoe is a vote of confidence from institutional investors. But the question is: confidence in what? The technology roadmap? The supply chain resilience? Or simply the narrative of national semiconductor self-sufficiency?
To answer that, I applied my standard audit framework—the same one I used in 2017 to detect integer overflow vulnerabilities in ICO contracts. The framework has three layers: capital efficiency, technology gap, and supply chain dependency.
Core: The On-Chain Evidence of Capital Urgency
Let’s start with the capital efficiency layer. CXMT’s free cash flow was negative ~20 billion yuan in 2024, while its capital expenditure ran at 50-60% of revenue—double the ratio of TSMC or Samsung. The company is bleeding cash into expansion. The over-allotment money is a drop in the bucket compared to the $150 billion needed for Fab 2 alone. Why would investors pay a 50-60x PE (vs. Samsung’s 20-30x) for a company that is still burning cash? Because the market is pricing in a future where CXMT captures a larger share of the DRAM market, driven by Chinese domestic demand and geopolitical tailwinds.
But the data tells a different story. Let’s examine the technology gap. My analysis of the process node roadmap shows that CXMT is 1.5-2 nodes behind Samsung and SK Hynix. The mass production of DDR5 at 1α nm is still ramping, while competitors are already shipping 1β nm and HBM3E. The gap in HBM packaging is even wider—3-4 years. CXMT has zero HBM revenue today. The company’s DDR5 yield is estimated at 70-80%, compared to 85-90% for the leaders. Every percentage point of yield loss directly compresses gross margin. CXMT’s gross margin of 15-25% is half of Samsung’s DRAM margin. The over-allotment money is likely earmarked for wafer fabrication equipment, especially ASML DUV lithography tools, which have a 18-24 month delivery lead time due to export controls.
Supply Chain Dependency: The Real Constraint
The supply chain audit reveals a critical vulnerability. CXMT’s import dependence on key equipment and materials remains above 80% for lithography, 70% for etching, and 90% for advanced photoresist. The company is on the U.S. BIS Entity List, restricting access to American equipment. It has pivoted to Japanese suppliers (TEL) and domestic alternatives (Naura, AMEC), but the domestic replacement rate is only 20-25% by value. The over-allotment cash may be used to pre-pay for Japanese equipment before potential export controls expand. This is a ticking clock.
Let’s map the risk scenarios. If the Netherlands tightens DUV export restrictions, CXMT’s Fab 2 timeline could slip by 2-3 years. If Japan joins the U.S.-led export control regime, the photoresist supply chain would be cut. The company’s own R&D pipeline is strong—it has proprietary DRAM cell design inherited from Qimonda—but without the ability to manufacture at scale, the IP is worthless.
Contrarian Angle: The Market Is Overlooking the Cost of the Gap
The consensus view is that CXMT’s over-allotment exercise signals strong institutional demand and a bright future for Chinese DRAM. I see a different narrative. The full exercise of the greenshoe without secondary market buying is unusual. It suggests that the underwriter did not need to support the price, but it also means that the share price is being propped up by a narrative, not by fundamentals. The 50-60x PE multiple is a bet on future growth, but growth is not guaranteed. The technology gap is not closing quickly; it is holding steady at 1.5-2 nodes. Every year of delay in DDR5 yield improvement or HBM launch reduces the net present value of those future cash flows.
Furthermore, the capital intensity of the DRAM industry creates a prisoner’s dilemma. CXMT must spend to stay in the race, but spending faster than revenue growth will keep free cash flow negative for years. The over-allotment money is a Band-Aid on a bullet wound. If the market turns bearish on DRAM pricing (the cycle is currently in an upswing, but cycles last 3-4 years), the company could face a liquidity crunch.
Takeaway: The Next 12-18 Months Are the Signal
The data is clear: CXMT is a high-risk, high-reward bet on Chinese semiconductor sovereignty. The over-allotment exercise is not a vote of confidence in the technology, but in the narrative. The next 12-18 months will reveal whether the narrative has substance. Watch for three metrics: DDR5 yield improvement above 80%, HBM3E tape-out, and the delivery of ASML DUV tools. If these signals are negative, the stock will correct. The market corrects; the data endures.
We trace the hash to find the human error. In this case, the error is not in the over-allotment exercise, but in the assumption that capital can solve all problems. It cannot. The data shows that the gap between CXMT and the leaders is not narrowing fast enough. The next cycle will separate the signal from the noise.